Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Dong-Churl Suh, Dong-Hyun Lee, Michael McGuire & Chul-Min Kim. (2011) Impact of rosiglitazone therapy on the lipid profile, glycemic control, and medication costs among type 2 diabetes patients. Current Medical Research and Opinion 27:8, pages 1623-1633.
Read now
Read now
Kenneth E. Truitt, Ronald B. Goldberg, Julio Rosenstock, Hubert S. Chou, Domenico Merante, Joseph Triscari & Antonia C. Wang. (2010) A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes. Current Medical Research and Opinion 26:6, pages 1321-1331.
Read now
Read now
Sheila A Doggrell. (2008) Clinical trials with thiazolidinediones in subjects with Type 2 diabetes – is pioglitazone any different from rosiglitazone?. Expert Opinion on Pharmacotherapy 9:3, pages 405-420.
Read now
Read now
E. Erdmann. (2005) Diabetes and cardiovascular risk markers. Current Medical Research and Opinion 21:sup1, pages S21-S28.
Read now
Read now
Charles G. Gegick & Michael D. Altheimer. (2004) Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors. Current Medical Research and Opinion 20:6, pages 919-930.
Read now
Read now
Articles from other publishers (32)
Omar M. Abdelfattah, Ahmed Sayed, Anas Al-Refaei, Jasmin Abdeldayem, Khaled Moustafa, Nicholas Elias & Yehia Saleh. 2023. Frontiers in Clinical Drug Research-Diabetes and Obesity: Volume 7. Frontiers in Clinical Drug Research-Diabetes and Obesity: Volume 7
117
167
.
Jacqueline C. Silva, Edson M. de Oliveira, Walter M. Turato, Gustavo H. G. Trossini, Vinícius G. Maltarollo, Marina G. R. Pitta, Ivan R. Pitta, Beatriz de las Heras, Lisardo Boscá, Martina Rudnicki & Dulcineia S. P. Abdalla. (2018) GQ-11: A new PPAR agonist improves obesity-induced metabolic alterations in LDLr−/− mice. International Journal of Obesity 42:5, pages 1062-1072.
Crossref
Crossref
Shari Wang, Leela Goodspeed, Katherine E Turk, Barbara Houston & Laura J den Hartigh. (2017) Rosiglitazone Improves Insulin Resistance Mediated by 10,12 Conjugated Linoleic Acid in a Male Mouse Model of Metabolic Syndrome. Endocrinology 158:9, pages 2848-2859.
Crossref
Crossref
Jacqueline C. Silva, Fernanda A. C?sar, Edson M. de Oliveira, Walter M. Turato, Gustavo L. Tripodi, Gabriela Castilho, Adriana Machado-Lima, Beatriz de las Heras, Lisardo Bosc?Marcelo M. Rabello, Marcelo Z. Hernandes, Marina G.R. Pitta, Ivan R. Pitta, Marisa Passarelli, Martina Rudnicki & Dulcineia S.P. Abdalla. (2016) New PPAR? partial agonist improves obesity-induced metabolic alterations and atherosclerosis in LDLr?/? mice. Pharmacological Research 104, pages 49-60.
Crossref
Crossref
Almudena Gómez-Hernández, Nuria Beneit, Sabela Díaz-Castroverde & Óscar Escribano. (2016) Differential Role of Adipose Tissues in Obesity and Related Metabolic and Vascular Complications. International Journal of Endocrinology 2016, pages 1-15.
Crossref
Crossref
Ekaterina A. Ivanova, Alessandro Parolari, Veronika Myasoedova, Alexandra A. Melnichenko, Yuri V. Bobryshev & Alexander N. Orekhov. (2015) Peroxisome proliferator-activated receptor (PPAR) gamma in cardiovascular disorders and cardiovascular surgery. Journal of Cardiology 66:4, pages 271-278.
Crossref
Crossref
Wang-Soo Lee & Jaetaek Kim. (2015) Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions. PPAR Research 2015, pages 1-18.
Crossref
Crossref
Bogna Grygiel-Górniak. (2014) Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review. Nutrition Journal 13:1.
Crossref
Crossref
Wei-Hsuan Hsu, Yu-Chun Huang, Bao-Hong Lee, Ya-Wen Hsu & Tzu-Ming Pan. (2013) The improvements of ankaflavin isolated from Monascus-fermented products on dyslipidemia in high-fat diet-induced hasmster. Journal of Functional Foods 5:1, pages 434-443.
Crossref
Crossref
J. P. H. Wilding. (2012) PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. Diabetes, Obesity and Metabolism 14:11, pages 973-982.
Crossref
Crossref
Giuseppe Derosa. (2010) Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus. Drugs 70:15, pages 1945-1961.
Crossref
Crossref
Nikolaos P.E. Kadoglou, Fotios Iliadis, Nikolaos Sailer, Zoi Athanasiadou, Ioulia Vitta, Alikistis Kapelouzou, Panayotis E. Karayannacos, Christos D. Liapis, Miltiadis Alevizos, Nikoletta Angelopoulou & Ioannis S. Vrabas. (2010) Exercise training ameliorates the effects of rosiglitazone on traditional and novel cardiovascular risk factors in patients with type 2 diabetes mellitus. Metabolism 59:4, pages 599-607.
Crossref
Crossref
Nikolaos P.E. Kadoglou, Hercules Tsanikidis, Alkistis Kapelouzou, Ioannis Vrabas, Ioulia Vitta, Panayotis E. Karayannacos, Christos D. Liapis & Nikolaos Sailer. (2010) Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. Metabolism 59:3, pages 373-379.
Crossref
Crossref
J.A. Dormandy, D.J. Betteridge, G. Schernthaner, V. Pirags & L. Norgren. (2009) Impact of peripheral arterial disease in patients with diabetes—Results from PROactive (PROactive 11). Atherosclerosis 202:1, pages 272-281.
Crossref
Crossref
Susan J. Appel, Mary Annette Wright, Alethea N. Hill & Fernando Ovalle. (2008) Uncovering Imperative Interventions in Prediabetes and Type 2 Diabetes. The Nurse Practitioner 33:8, pages 20-26.
Crossref
Crossref
N. P. E. Kadoglou, F. Iliadis, N. Angelopoulou, D. Perrea, C. D. Liapis & M. Alevizos. (2008) Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus. Diabetic Medicine 25:3, pages 333-340.
Crossref
Crossref
Li-Fen Liu, Aparna Purushotham, Angela A. Wendel & Martha A. Belury. (2007) Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice. American Journal of Physiology-Gastrointestinal and Liver Physiology 292:6, pages G1671-G1682.
Crossref
Crossref
M. Hanefeld. (2007) Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. International Journal of Clinical Practice 61, pages 20-27.
Crossref
Crossref
Erland Erdmann, John A. Dormandy, Bernard Charbonnel, Massimo Massi-Benedetti, Ian K. Moules & Allan M. Skene. (2007) The Effect of Pioglitazone on Recurrent Myocardial Infarction in 2,445 Patients With Type 2 Diabetes and Previous Myocardial Infarction. Journal of the American College of Cardiology 49:17, pages 1772-1780.
Crossref
Crossref
Anjli Maroo & W.H. Wilson Tang. 2007. Therapeutic Lipidology. Therapeutic Lipidology
149
158
.
L Maria Gutschi, Janine C Malcolm, Colette M Favreau & Teik Chye Ooi. (2016) Paradoxically Decreased HDL-Cholesterol Levels Associated with Rosiglitazone Therapy. Annals of Pharmacotherapy 40:9, pages 1672-1676.
Crossref
Crossref
Angela M. Taylor & Coleen A. McNamara. (2006) Are thiazolidinediones good or bad for the heart?. Current Diabetes Reports 6:5, pages 378-383.
Crossref
Crossref
Michael T. Tran, Maria D. Navar & Mayer B. Davidson. (2006) Comparison of the Glycemic Effects of Rosiglitazone and Pioglitazone in Triple Oral Therapy in Type 2 Diabetes. Diabetes Care 29:6, pages 1395-1396.
Crossref
Crossref
Gregg D Simonson & David M Kendall. (2006) Different actions of peroxisome proliferator-activated receptors: molecular mechanisms and clinical importance. Current Opinion in Endocrinology & Diabetes 13:2, pages 162-170.
Crossref
Crossref
Marion R. Wofford, Deborah S. King & T. Kristopher Harrell. (2007) Drug‐Induced Metabolic Syndrome. The Journal of Clinical Hypertension 8:2, pages 114-119.
Crossref
Crossref
Vered Sheena, Rachel Hertz, Ina Berman, Janna Nousbeck & Jacob Bar-Tana. (2005) Transcriptional suppression of human microsomal triglyceride transfer protein by hypolipidemic insulin sensitizers. Biochemical Pharmacology 70:11, pages 1548-1559.
Crossref
Crossref
M. Ledl, J. Hohenecker, C. Francesconi, I. Roots, M. F. Bauer & M. Roden. (2005) Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone. Diabetologia 48:10, pages 1996-1998.
Crossref
Crossref
Bart Staels & Jean-Charles Fruchart. (2005) Therapeutic Roles of Peroxisome Proliferator–Activated Receptor Agonists. Diabetes 54:8, pages 2460-2470.
Crossref
Crossref
Christodoulos S. Flordellis, Ioannis Ilias & Athanasios G. Papavassiliou. (2005) New therapeutic options for the metabolic syndrome: what's next?. Trends in Endocrinology & Metabolism 16:6, pages 254-260.
Crossref
Crossref
Ronald B. Goldberg, David M. Kendall, Mark A. Deeg, John B. Buse, Anthony J. Zagar, Jane A. Pinaire, Meng H. Tan, Mehmood A. Khan, Alfonso T. Perez & Scott J. Jacober. (2005) A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia. Diabetes Care 28:7, pages 1547-1554.
Crossref
Crossref
Maria H. Clough, David J. Schneider, Burton E. Sobel, Morris F. White, Marilyn P. Wadsworth & Douglas J. Taatjes. (2016) Attenuation of Accumulation of Neointimal Lipid by Pioglitazone in Mice Genetically Deficient in Insulin Receptor Substrate-2 and Apolipoprotein E. Journal of Histochemistry & Cytochemistry 53:5, pages 603-610.
Crossref
Crossref
Vinod Mattoo, David Eckland, Mario Widel, Santiago Duran, Carmen Fajardo, Jorma Strand, Debbie Knight, Loren Grossman, David Oakley & Meng Tan. (2005) Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: Results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clinical Therapeutics 27:5, pages 554-567.
Crossref
Crossref